

Index of Plaintiff States' Excerpts of Administrative Record (EAR)
State of Washington, et al. v. United States
Food and Drug Administration, et al.
No. 1:23-cv-03026-TOR

VOLUME A			
Administrative Record			
Index Page Number	Document Name	Document Date	Excerpted AR Number
EAR1-11	FDA, Risk Assessment and Risk Mitigation Review(s) (Korlym) (FDA 292-0306)	Jan. 1, 2012	FDA 292, FDA 294, FDA 296-304
EAR12-13	Korlym Summary Review (FDA 307-0330)	Feb. 17, 2012	FDA 307, FDA 310,
EAR14-18	FDA, Summary Review (Mifeprex) (FDA 412-439)	Mar. 29, 2016	FDA 412, FDA 434-37
EAR19-22	CDER Application No. 020687Orig1s020 Medical Review(s) (FDA 527-634)	Mar. 29, 2016	FDA 527, FDA 537, FDA 539, FDA 574
EAR23-30	FDA, REMS Review & Supporting Materials (Mifeprex) (FDA 673-709)	Mar. 29, 2016	FDA 673-674, FDA 679-81, FDA 698, FDA 704-705
EAR31-33	FDA, Citizen Petition Response Letter to Am. Assoc. of Pro-Life Obstetricians & Gynecologists ("AAPLOG") et al. (FDA 856-88)	Mar. 29, 2016	FDA 856, FDA 880-881 n. 69
EAR34-35	Tab F, RU-486 Action Date is Sept. 30; Allen Named Reproductive Division Director, The Pink Sheet, Vol. 62; No. 24; Pg. 14, (FDA 1064-1066)	June 12, 2000	FDA 1065-66

EAR36-37	F.D.A. Adds Hurdles in Approval of Abortion Pill, New York Times (FDA 1143-1145)	June 8, 2000	FDA 1144-1145
EAR38-39	Letter from Kelly Blanchard, President, Ibis Reproductive Health et al., to FDA (FDA 1245-53)	Nov. 3, 2015	FDA 1245, FDA 1247
EAR40-42	Letter from Soc’y of Family Planning (“SFP”) et al., to FDA (FDA 1254-62)	Feb. 4, 2016	FDA 1254, FDA 1256, FDA 1257
EAR43-44	Letter from Hal C. Lawrence, III, Exec. VP & CEO, Am. Coll. Of Obstetricians & Gynecologists (“ACOG”), to FDA (FDA 1263-64)	Nov. 4, 2015	Entire range
VOLUME B			
Administrative Record			
EAR45-49	Sixteen Years of Overregulation: Time to Unburden Mifeprex Mifeprex REMS Study Group, New England Journal of Medicine (2019 CP 370-374)	2017	Entire range
EAR50-51	Elizabeth Raymond, et al., <i>Increasing Access to Abortion with Telemedicine</i> , Viewpoint, JAMA Internal Medicine, May 2016 Volume 176, Number 5 (2019 CP 389-390)	2016	Entire range
EAR 52-53	Courtney A. Schreiber, et al., <i>Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss</i> , N. Eng. J. Med., 2161-70 (2019 CP 402-411)	2018	2019 CP 402-03
EAR54-55	FDA, Citizen Petition Response Letter to AAPLOG and Am. Coll. of Pediatricians (2019 CP 628-68)	Dec. 16, 2021	2019 CP 629, 2019 CP 648

VOLUME C			
Administrative Record			
EAR56-58	ACOG/Society for Maternal Fetal Medicine Letter to Hahn/FDA Re: Docket Number: FDA-2020-D-1106; Policy for Certain REMS Requirements During the COVID-19 Public Health Emergency Guidance for Industry and Health Care Professionals (2021 ED 1-3)	Apr. 20, 2020	Entire range
EAR59-61	ACOG: <i>Position Statement: Improving Access to Mifepristone for Reproductive Health Indications</i> (2021 ED 11-13)	June 2018	Entire Range
EAR62-66	Nat'l Acads. of Scis., Eng'g & Med., The Safety & Quality of Abortion Care in the United States (2021 ED 126-348)	2018	2021 ED 126-27, 2021 ED 147, 2021 ED 195 2021 ED 240
EAR67-38	Letter of Woodcock to ACOG & Society for Maternal-Fetal Medicine (2021 ED 510-511)	Apr. 12, 2021	Entire range
EAR69-74	Letter of State Attorneys General to Alex Azar, Secretary, U.S. Dept. of Health & Human Servs, and Dr. Stephen Hahn, Commissioner (2021 REMS 35-40)	Mar. 30, 2020	Entire range
EAR75	Letter from AAFP to Dr. Norman Sharpless, Acting Commissioner, U.S. Food & Drug Admin. (2021 REMS 42)	June 20, 2019	Entire range
EAR76-80	Letter from 500 Women Scientists et al. to Dr. Stephen Hahn, Commissioner, U.S. Food & Drug Admin. (2021 REMS 44-48)	Apr. 6, 2020	Entire range

EAR81-82	Guttmacher Inst., <i>Medication Abortion</i> (2021 REMS 72-83)	Nov. 12, 2019	2021 REMS 72- 73
EAR83-84	Advancing New Standards in Reproductive Health, Analysis of Medication Abortion Risk and the FDA Report “Mifepristone US. Post-Marketing Adverse Events Summary through 12/31/2018 (2021 REMS 84-85)	Apr. 2019	Entire range
EAR85-86	Jane E. Henney & Helene D. Gayle, <i>Time to Reevaluate U.S. Mifepristone Restrictions</i> , 381 N. Eng. J. Med., 597-98 (2021 REMS 166-167)	2019	Entire range
EAR87-89	Letter from Maryland General Assembly Members to Dr. Stephen Hahn, Commissioner, U.S. Food & Drug Admin. (2021 REMS 562-64)	Oct. 6, 2020	Entire range
EAR90-91	Am. Coll. of Obstetricians & Gynecologists, Prac. Bull. No. 200, <i>Early Pregnancy Loss</i> , 132 Obstetrics & Gynecology e198-e207 (2021 REMS 578-88)	2018	2021 REMS 578, 2021 REMS 581
EAR92-96	Elizabeth G. Raymond & David A. Grimes, <i>The Comparative Safety of Legal Induced Abortion and Childbirth in the United States</i> , 119 Obstetrics & Gynecology 215-19 (2021 REMS 695-99)	2012	Entire range
EAR97-103	Emily E. Petersen, et al., <i>Vital Signs: Pregnancy-Related Deaths, United States, 2011-2015, and Strategies for Prevention</i> , 13 States, 2013-2017, 68 Morbidity & Mortality Weekly Report, 423-29 (2021 REMS 700-06)	2019	Entire range

EAR104-106	ACOG & SFP, Practice Bulletin No. 225, Medication Abortion Up to 70 Days of Gestation, 136 Obstetrics & Gynecology e31-e47 (2021 REMS 748-64)	Oct. 2020	2021 REMS 748, 2021 REMS 751, 2021 REMS 756
EAR107-108	Daniel Grossman, et al., <i>Medication Abortion with Pharmacist Dispensing of Mifepristone</i> , 137 Obstetrics & Gynecology, 613-22 (2021 REMS 000772-81)	Apr. 2021	2021 REMS 772, 2021 REMS 779
EAR109-110	Debra B. Stulberg, et al., <i>Abortion Provision Among Practicing Obstetrician-Gynecologists</i> , 118 Obstetrics & Gynecology, 609-14 (2021 REMS 921-31)	2011	2021 REMS 921, 2021 REMS 925
EAR111-116	Letter from SFP Bd. of Dirs., to FDA (2021 REMS 950-55)	Aug. 11, 2021	Entire range
EAR117-118	Laura Schummers et al., <i>Do Medication Abortion Complications Increase When Mifepristone Is Available Without Regulations Restricting Practice? A Population based Study Using Linked Health Administrative Data from Canada</i> , 47 BMJ Sex. Reprod. Health. 2-3 (2021 REMS 956-57)	2021	Entire range
EAR119-121	Daniel Grossman et al., <i>Induced Abortion Provision Among a National Sample of Obstetrician-Gynecologists</i> , 133 Obstetrics & Gynecology 477-83 (2021 REMS 966-72)	2019	2021 REMS 966, 2021 REMS 970-71

EAR122-127	Silpa Srinivasulu et al., US clinicians' Perspectives on How Mifepristone Regulations Affect Access to Medication Abortion and Early Pregnancy Loss Care in Primary Care, 104 Contraception 92-97 (2021 REMS 973-78)	2021	Entire range
EAR128-132	Danielle Calloway et al., <i>Mifepristone Restrictions and Primary Care: Breaking the Cycle of Stigma Through a Learning Collaborative Model in the United States</i> , 104 Contraception 24-28 (2021 REMS 979-83)	2021	Entire range
EAR133-34	Sarah Munro et al., <i>Perspectives Among Canadian Physicians on Factors Influencing Implementation of Mifepristone Medical Abortion: A National Qualitative Study</i> , 18 Annals Family Med. 413-21 (2021 REMS 984-92)	2020	2021 REMS 984, 2021 REMS 991
EAR135-40	Kayla N. Rasmussen et al., <i>Expanding Access to Medication Abortion Through Pharmacy Dispensing of Mifepristone: Primary Care Perspectives from Illinois</i> , 104 Contraception 98-103 (2021 REMS 993-98)	2021	Entire range
EAR141-42	Letter from Dr. Graham Chelius, SFP & Cal. Acad. of Family Physicians, to FDA (2021 REMS 1159-67)	Sept. 29, 2021	2021 REMS 1159, 2021 REMS 1163
EAR143-44	Cong. of Delegates, Am. Acad. of Fam. Physicians (“AAFP”), <i>Resolution No. 506 (Cosponsored C) - Removing Risk Evaluation and Mitigation Strategy (REMS) Categorization of Mifepristone</i> (2021 REMS 1168-71)	May 24, 2018	2021 REMS 1168-69

EAR145-147	Alice F. Cartwright, et al., <i>Identifying National Availability of Abortion Care and Distance from Major US Cities: Systematic Online Search</i> , 20 J. Med. Internet Res. E186 (2021 REMS 1185-97)	2018	2021 REMS 1185-86, 2021 REMS 1193
EAR148-149	Memorandum: Mifepristone and All Adverse Events NDA 020687 and ANDA 091178. RCM # 2007-525 (2021 REMS 1390-1401)	Dec. 16, 2021	2021 REMS 1390, 2021 REMS 1393
EAR150-198	REMS Modification Rationale Review (Mifepristone) 2021 REMS 1561-1609	Dec. 16, 2021	Entire range
EAR199-201	Chelius Appendix, Exhibit 1, Declaration of Graham T. Chelius, M.D. (2021 REMS 1923-1944)	Apr. 14, 2021	2021 REMS 1924, 2021 REMS 1937-38
EAR202-204	Chelius Appendix, Exhibit 3, Declaration of Joey Banks, M.D. (2021 REMS 1959-64)	Apr. 12, 2021	2021 REMS 1960, 2021 REMS 1963-64
EAR205-207	Chelius Appendix, Exhibit 6, Declaration of Charisse M. Loder, M.D., M.SC. (2021 REMS 1982-95)	Apr. 14, 2021	2021 REMS 1983, 2021 REMS 1991-92
EAR208-209	Letter from ACOG to FDA (2021 REMS 2051-2052)	Oct. 6, 2021	Entire range
VOLUME D			
Administrative Record			
EAR210-237	Citizen Petition from ACOG et al., to FDA (2022 CP 71-98)	Oct. 4, 2022	Entire range

EAR238-239	Laura Schummers et al., <i>Abortion Safety and Use with Normally Prescribed Mifepristone in Canada</i> , 386 New Eng. J. Med. 57-67 (2022 CP 99-109)	Jan. 6, 2022	2022 CP 99, 2022 CP 108
EAR240-243	Citizen Response Letter from U.S. Food & Drug Admin. To American College of Obstetricians & Gynecologists (2022 CP 110-113)	Jan. 3, 2023	Entire range
VOLUME E			
Administrative Record			
EAR244-245	NDA Type A Meeting Request Letter (2023 SUPP 1-12)	Mar. 11, 2022	2023 SUPP 1, 2023 SUPP 10
EAR246-251	Letter from Maureen G. Phipps, CEO, ACOG & James L. Madara, CEO, AMA, to FDA re: actions related to mifepristone (2023 SUPP 32-37)	June 21, 2022	Entire range
EAR252-253	Carolyn L. Westhoff, <i>A better medical regimen for the management of miscarriage</i> , 378 N. Eng. J. Med., 2232-33 (2023 SUPP 69-70)	2018	Entire range
EAR254-256	World Health Org., Medical Management of Abortion (2023 SUPP 088-159)	2018	2023 SUPP 88, 2023 SUPP 104-05
EAR257-261	Donna L. Hoyert, <i>Maternal Mortality Rates in the United States, 2020</i> , National Center for Health Statistics (2023 SUPP 180-84)	Feb. 2022	Entire range

EAR262	Nisha Verma & Scott A. Shainker, <i>Maternal mortality, abortion access, and optimizing care in an increasingly restrictive United States: A review of the current climate</i> , Seminars in Perinatology (2023 SUPP 201-09)	2020	2023 SUPP 201
EAR263	M. Antonia Biggs et al., <i>Women's Mental Health and Well-being 5 Years After Receiving or Being Denied an Abortion: A Prospective, Longitudinal Cohort Study</i> , 74 JAMA Psychiatry 169-78 (2023 SUPP 229-38)	2017	2023 SUPP 229
EAR264-268	NDA amendment responding to 7/22/2022 information request (2023 SUPP 451-78)	Aug. 26, 2022	2023 SUPP 455, 2023 SUPP 460-63
EAR269-270	FDA Integrated Memorandum re All Adverse Events (Mifepristone REMS) (2023 SUPP 1040-51)	Dec. 22, 2022	2023 SUPP 1040, 2023 SUPP 1042
EAR271	U.S. Food & Drug Admin., <i>Mifepristone U.S. Post-Marketing Adverse Events Summary through 6/30/2022</i> (finalized Nov. 9, 2022) (2023 SUPP 1052-53)	Nov. 9, 2022	2023 SUPP 1052
EAR272-310	Joint Summary Review (Mifepristone REMS) (2023 SUPP 1112-50)	Jan. 3, 2023	Entire range
EAR3311-13	NAF, 2020 Violence and Disruption Statistics (2023 SUPP 1151-59)	2020	2023 SUPP 1151-53
EAR314-316	Amanda Musa, <i>Wyoming Authorities Search for a Suspect Believed to Have Set an Abortion Clinic on Fire</i> , CNN WIRE (2023 SUPP 1160-62)	June 11, 2022	Entire range

EAR317-319	Mifeprex 2023 Labeling and Medication Guide (2023 SUPP 1471-89)	Jan. 2023	2023 SUPP 1471-73
EAR320-322	Mifepristone 2023 Labeling and Medication Guide (2023 SUPP 1490-1509)	Jan. 2023	2023 SUPP 1490-1492
EAR323	Patient Agreement Form (Mifeprex) (2023 SUPP 001510)	Jan. 2023	Entire range

VOLUME F**Materials Available on FDA and HHS Webpages**

Index Page No.	Webpage or Document Name	Date
EAR324-325	Risk Evaluation and Mitigation Strategies	accessed Oct. 9, 2024
EAR3326	FDA at a Glance	accessed Oct. 9, 2024
EAR327-332	Approved Risk Evaluation and Mitigation Strategies (REMS) homepage	accessed Oct. 9, 2024
EAR333-338	FDA, REMS Document: Opioid Analgesic REMS Program	Apr. 2021
EAR339-342	Remarks by Secretary Xavier Becerra at the Press Conference in Response to President Biden's Directive Following Overturning of <i>Roe v. Wade</i>	June 28, 2022